meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
2
mHNSCC - L1 - PDL1 positive
4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
4
mHNSCC - L2 - PDL1 negative
2
mHNSCC - L2 - PDL1 positive
1
hepatocell cancer (HCC)
1
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus 5FU plus platin
versus all
vs HER inhibitor
vs EGFR inhibitor
vs cetuximab based chemotherapy
vs cetuximab plus platin plus 5FU
All patients
Age < 65y (younger)
Age > 65y
cancer type (metastatic)
cancer type (recurrent)
ECOG 0
ECOG 1
Gender, female
Gender, male
P16 negative (HPV)
P16 positive (HPV)
smoker (Current)
smoker (Former)
smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
deaths (OS) (extension)
DOR
objective responses (ORR)
progression or deaths (PFS)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
Adrenal insufficiency TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Blood and lymphatic system disorders TRAE (grade 3-4)
Blood creatinine increased TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Endocrine disorders TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
General disorders and administration site conditions TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Metabolism and nutrition disorders TRAE (grade 3-4)
Mucosal inflammation TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Skin and subcutaneous tissue disorders TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Uveitis TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Weight decreased TRAE (grade 3-4)
Abdominal pain AE (grade 3-4)
Acute kidney injury AE (grade 3-4)
Anaemia AE (grade 3-4)
Asthenia AE (grade 3-4)
Blood and lymphatic system disorders AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Febrile neutropenia AE (grade 3-4)
Gastrointestinal disorders AE (grade 3-4)
General disorders and administration site conditions AE (grade 3-4)
Hypertension AE (grade 3-4)
Increase AST AE (grade 3-4)
Leucopenia AE (grade 3-4)
Metabolism and nutrition disorders AE (grade 3-4)
Mucosal inflammation AE (grade 3-4)
Nausea AE (grade 3-4)
Nervous system disorders AE (grade 3-4)
Neutropenia AE (grade 3-4)
Pneumonitis AE (grade 3-4)
Rash AE (grade 3-4)
Renal and urinary disorders AE (grade 3-4)
Respiratory, thoracic and mediastinal disorders AE (grade 3-4)
Sepsis AE (grade 3-4)
Skin and subcutaneous tissue disorders AE (grade 3-4)
Stomatitis AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Vascular disorders AE (grade 3-4)
Vomiting AE (grade 3-4)
Weight decreased AE (grade 3-4)
deaths (OS)
mHNSCC - L1 - all population
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
versus cetuximab plus platin plus 5FU
pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU
1
certainty unassessable
statistically conclusive
-21%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open